Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Major focus is the epidemiology of chronic and disabling conditions, using arthritis and musculoskeletal disorders as models for issues relating to quality of life, aging, and access to health care. This research includes: major population surveys for estimating the prevalence of bone and joint disorders and planning community services for people with disabling conditions; estimating the impact of musculoskeletal disorders and disability through the analysis of large scale data sets; and applied research directed towards the provision and evaluation of services for people with arthritis. Current research focuses population-based and clinical studies to better understand the characteristics and impact of musculoskeletal disorders, particularly osteoarthritis.
Osteoarthritis; epidemiology; health services research; quality of life; musculoskeletal
Health services research; outcomes; value-based care
Expertise in hip biomechanics and the design and development of both primary and revision total hip implants. Special interest in femoral offsets and femoral neck design. Previous implant design and development have included:
Hip; knee; revision; biomechanics; implants
As a physiotherapist trained in clinical epidemiology, my research focuses on understanding predictors of outcome in people with musculoskeletal conditions, mainly osteoarthritis (OA), with the goal of bridging the gap between research, implementation of interventions and processes of care to achieve improved patient outcomes. I also develop and evaluate patient-reported outcome measures.
Osteoarthritis; health services research; outcome evaluation; patient-reported outcomes; rehabilitation
Understanding the role of systemic inflammation, obesity and osteoarthritis. The guiding hypothesis for this work is that OA is not a single disease entity. My work is focused on identifying important subgroups of individuals, whether biochemical, inflammatory and/or genetic, complemented with patient-reported measures. Identification of these subgroups may suggest different disease etiologies, and responses to medical and surgical treatment.
Advancing the understanding of the pain and functional outcomes and patient satisfaction following knee replacement surgery. Approximately 15% to 30% of people report little to no improvement in pain and function following knee replacement surgery. The present goal of this work is to understand the role of a patient’s individual biology as a predictor and as a therapeutic target for improving knee replacement outcomes.
Orthopaedic surgeon; osteoarthritis; inflammation; hip replacement; knee replacement
The group focuses on computational biology and medicine, and specifically on creating explainable models for chronic diseases. We develop and apply integrative computational biology tools across major high-throughput data in multigenic diseases in order to identify prognostic/predictive signatures, find clinically relevant combination therapies, and develop accurate models of disease-altered networks and pathways, and drug mechanism of action.
Integrative computational biology; data mining; machine learning
Jurisica Lab: Data Science Discovery Centre for Chronic Diseases
The Keating Lab has focused a longtime study of the biology of bone marrow derived mesenchymal stromal cells (MSCs) towards treating osteoarthritis (OA). We have identified a molecular signature of potency for MSCs with high anti-inflammatory activity for testing in animal models of OA. We are further investigating engineered, safe, non-immunogenic iPSC-derived, molecular signature-defined MSCs to develop more effective, unlimited therapeutic cells. We will translate these studies to early phase OA cell therapy clinical trials. We are also investigating the microRNA signatures of MSC differentiation to chondrogenic and osteogenic cells to identify specific pathways that promote regeneration of OA damaged tissue. We are also investigating stromal cells present in "bone marrow lesions" as a means to reduce OA pain.
Mesenchymal stromal cells; cell therapy; clinical translation research; hematopoiesis; immune modulation
Orthopedic surgery; spine surgery
Health systems research focusing on development, delivery and evaluation of value-based care.
Health systems research;outcomes; value-based care
A clinical trial was used to test the hypotheses that a single intra-articular (ia) injection of autologous BM-MSC (suspended in autologous serum) would be safe and effective in managing knee OA; and that the needed dose-escalation clinical trial will identify an optimal MSC dosage to treat knee OA.
Cartilage; arthroscopy; sports; ligaments; arthritis
University of Toronto Orthopaedic Sports Medicine (UTOSM) Program
Suggesting that osteoarthritis (OA) is not a single disease entity, I am working to identify distinct OA subgroups within clinical and population-based OA samples, with particular focus on inflammation and differences by sex. Distinct subgroups may have different causes, disease trajectories, and/or responses to medical/surgical treatment. Consequently, there would be a need for a more refined epidemiological profiling of OA, possible changes to OA prevention and management/treatment strategies, and a need to carefully consider subgroups in designing clinical trials. Work is underway investigating.
Epidemiology; osteoarthritis; patient-reported outcomes
Yoga Raja Rampersaud
Spine; orthopedic surgery; spine surgery; clinical outcomes
Orthopedic surgery; arthritis; health informatics; clinician workflow
Leveraging my industry and clinical trial experience, I have created a translational lab focused on developing cellular therapies for osteoarthritis.
My research program has dual focii:
Under this platform, the role of monocytes/macrophages in joint inflammation and degradation are being investigated to identify molecular and cellular metabolic regulators of monocyte/macrophage dysregulation.
Mesenchymal stromal cells (MSCs) with anti-inflammatory and immunomodulatory properties are promising therapeutic for OA as demonstrated in our first-in-Canada MSC trial in knee OA. I am using manufacturing solutions to enhance MSC properties to develop next generation potent MSC products for OA.
Mesenchymal stromal cells (MSCs); monocyte/macrophage; cell therapy; clinical trials; cell manufacturing